Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Acquired hemolytic anemia Stories

2014-04-10 12:36:37

New technology can reduce adverse reactions and decrease blood bank costs, report investigators in The Journal of Molecular Diagnostics Scientists in France have designed a new system for molecular blood group typing that offers blood banks the possibility of extensive screening of blood donors at a relatively low cost. Their approach is described in the current issue of The Journal of Molecular Diagnostics. Although blood transfusion is generally safe, alloimmunization (when an...

2014-03-31 16:27:38

OAKLAND, Calif., March 31, 2014 /PRNewswire/ -- Machaon Diagnostics today announced the availability of its "aHUS Genetic Panel(TM)" (patent pending) to genetically confirm atypical Hemolytic Uremic Syndrome (aHUS) with a turnaround time of 48 hours. The 48 hour timeframe is a dramatic advancement over other approaches which offer results in 4-13 weeks. The speed of the aHUS Genetic Panel(TM) allows the test to impact patient care in acute settings, enabling doctors to better serve...

2014-01-16 08:27:51

New testing approach uses Next Gen Sequencing platform MILWAUKEE, Jan. 16, 2014 /PRNewswire/ -- BloodCenter of Wisconsin's Diagnostic Laboratories today announced the availability of a comprehensive genetic evaluation using next generation sequencing (NGS) technology for patients with Atypical Hemolytic Uremic Syndrome (aHUS). BloodCenter is among the first to offer clinical diagnostics using NGS, providing a dramatically shortened timeline for obtaining test results for this...

2013-11-10 00:21:29

- New Data from the Largest Prospective Trial of Adult Patients with aHUS and First Prospective Trial in Pediatric Patients with aHUS Confirm the Safety and Efficacy Profile of Soliris -- - ASN Meeting Also Features Three-year Update Data Highlighting Long-term Benefits of Chronic Soliris Therapy in Patients with aHUS - CHESHIRE, CT, Nov. 9, 2013 /CNW/ - Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers presented data from four clinical trials, all...

2013-09-09 12:27:47

Novel Humanized Antibody Approach May Lead to Safer, More Cost Effective Treatment CLEVELAND, Sept. 9, 2013 /PRNewswire-USNewswire/ -- NovelMed Therapeutics (www.novelmed.com) announced the receipt of a combined $1.43 million SBIR Grant from the NIH. The first installment of the award (for $542,572) will be used to evaluate NovelMed's lead candidate's therapeutic superiority for treating Paroxysmal Nocturnal Hemoglobinuria (PNH). Subsequent funding, to be released on demonstration...

2013-07-25 12:26:35

DUBLIN, July 25, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/6r3vhf/acquired_orphan) has announced the addition of the "Acquired Orphan Blood Diseases Therapeutics Market to 2019 - Search for Disease Modifying Drugs Central to Unlocking Premium Pricing Potential" [http://www.researchandmarkets.com/research/6r3vhf/acquired_orphan ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )...

2008-11-10 15:00:07

CHESHIRE, Conn., Nov. 10 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. today announced that the American Society of Hematology (ASH) has published additional data relating to Soliris(R) (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Data also have been published regarding initial experience with eculizumab in patients with two other rare diseases (Atypical Hemolytic Uremic Syndrome and Cold Agglutinin Disease). Abstracts will be presented...